Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3584]

Clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

Clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

Cellular messengers improve cancer therapy

Cellular messengers improve cancer therapy

World's first clinical trial with CAR-T technology for patients with T-cell leukaemia subtype authorised

World's first clinical trial with CAR-T technology for patients with T-cell leukaemia subtype authorised

FDA grants approval to atezolizumab for alveolar soft part sarcoma

FDA grants approval to atezolizumab for alveolar soft part sarcoma

Why don’t T cells destroy solid tumours during immunotherapy?

Why don’t T cells destroy solid tumours during immunotherapy?

Bioengineered synthetic gene circuits enhance cancer immunotherapies

Bioengineered synthetic gene circuits enhance cancer immunotherapies

ASH 2022: MajesTEC-2 trial of teclistamab-cqyv in combination with daratumumab and hyaluronidase-fihj and lenalidomide shows clinical activity in RRMM

ASH 2022: MajesTEC-2 trial of teclistamab-cqyv in combination with daratumumab and hyaluronidase-fihj and...

ASH 2022: Researchers present new approach to understanding challenging CAR T-cell toxicities

ASH 2022: Researchers present new approach to understanding challenging CAR T-cell toxicities

ASH 2022: CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial

ASH 2022: CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial

New technology for inhibiting T cell exhaustion and reinvigorating exhausted T cells, which is essential for immune cell therapy of solid cancer

New technology for inhibiting T cell exhaustion and reinvigorating exhausted T cells, which is essential for...

More from ecancer